[Skip to Content]
[Skip to Content Landing]
Comment & Response
October 2016

Use of Clozapine in Schizophrenia

Author Affiliations
  • 1Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta
 

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Psychiatry. 2016;73(10):1097-1098. doi:10.1001/jamapsychiatry.2016.1241

To the Editor Does clozapine offer additional therapeutic benefit to patients who have received inadequate therapeutic benefit from other antipsychotic medications (APMs)? This is the question Samara et al1 aimed to address in their article in JAMA Psychiatry.

When Kane et al2 undertook the comparison of clozapine and chlorpromazine, “inadequate therapeutic benefit” was straightforward: tens of thousands of patients were state-hospitalized in the long-term because they were profoundly psychotic, violent, and/or self-injurious. In 268 of them whose condition did not improve during a high-dose haloperidol lead-in, clozapine handily beat chlorpromazine on psychopathology change. Those of us working in state hospitals as clozapine became available for clinical use noted that the hospitals became less dangerous and then less populous.

×